Compare Novartis AG (NVS) vs First Trust NASDAQ 100 Technology Index Fund (QTEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs First Trust NASDAQ 100 Technology Index Fund — how do they compare? Novartis AG trades at $143.75 (market cap $268.57B), while First Trust NASDAQ 100 Technology Index Fund trades at $331.55 (market cap $4.10B). The key difference: Novartis AG is far larger — about 65.5× First Trust NASDAQ 100 Technology Index Fund's market cap, and Novartis AG pays a 3.31% dividend while First Trust NASDAQ 100 Technology Index Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and First Trust NASDAQ 100 Technology Index Fund for 40 Days on average.
| NVS | QTEC | |
|---|---|---|
Market Cap | $268.57B | $4.10B |
Volume | 1,532,573 | 264,303 |
Sector | Health | Broad Market / Factor |
52-Week High | $168.62 | $340.28 |
52-Week Low | $121.80 | $207.03 |
Typical Hold Time | 82 Days | 40 Days |
Enterprise Value | $309.89B | — |
Dividend Yield | 3.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVS trades at $143.11, down 0.12% on the day, with a bearish technical signal and mixed earnings history including a recent Q1 2026 miss. The company maintains strong profitability with a 22.5% net income margin and 30.55% ROE, while recent news highlights a major $7.8B licensing deal with China's Abogen and ongoing investor scrutiny following clinical trial setbacks.
The outlook is cautious; analyst consensus is a Hold with a $146 price target, but risks include pipeline disappointments and M&A execution. Upside hinges on successful drug launches and deal integration, while downside stems from competitive pressures and regulatory challenges.
QTEC trades at $331.55, down 1.27% today, with a bullish technical signal from moving averages but neutral oscillators. The ETF provides equal-weighted exposure to NASDAQ-100 technology stocks, though key valuation and profitability ratios are unavailable in the provided data. Recent analysis highlights the software sector's undervaluation relative to historical averages, positioning QTEC as a liquid alternative to similar tech ETFs.
The outlook remains cautiously optimistic given the ETF's broad tech exposure and bullish technical trend, but risks include sector volatility and macroeconomic pressures. Investors should weigh the ETF's diversification benefits against potential headwinds in the technology sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About First Trust NASDAQ 100 Technology Index Fund
QTEC is an ETF that seeks to track the performance of the NASDAQ-100 Technology Sector Index. The fund provides targeted exposure to companies within the NASDAQ-100 that are classified as technology or telecommunications companies, focusing on firms involved in software, hardware, and related services. QTEC is a tool for investors seeking focused exposure to high-growth, large-cap technology companies listed on the NASDAQ exchange.
Read more on QTEC →
